Niki Karachaliou

Niki Karachaliou

UNVERIFIED PROFILE

Are you Niki Karachaliou?   Register this Author

Register author
Niki Karachaliou

Niki Karachaliou

Publications by authors named "Niki Karachaliou"

Are you Niki Karachaliou?   Register this Author

100Publications

3895Reads

6Profile Views

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.

Expert Rev Respir Med 2019 Oct 19;13(10):1019-1028. Epub 2019 Aug 19.

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2019.1656068DOI Listing
October 2019

Novel molecular targets for the treatment of lung cancer.

Curr Opin Oncol 2019 Oct 9. Epub 2019 Oct 9.

Thoracic Oncology Unit, National Cancer Institute (INCan), Mexico City, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000590DOI Listing
October 2019

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

Onco Targets Ther 2019 13;12:4567-4575. Epub 2019 Jun 13.

Molecular and Cellular Oncology Laboratory, Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S174548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580130PMC
June 2019

Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2019 May 21;20(3):167-177. Epub 2019 Feb 21.

Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.005DOI Listing
May 2019

Co-mutations in EGFR driven non-small cell lung cancer.

EBioMedicine 2019 Apr 20;42:18-19. Epub 2019 Mar 20.

Merck KgaA, Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.03.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491418PMC
April 2019

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 22;14(2):304-310. Epub 2018 Nov 22.

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain; Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Medical Oncology Service, Hospital General de Valencia, Valencia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.168DOI Listing
February 2019

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).

EBioMedicine 2019 Jan 22;39:207-214. Epub 2018 Nov 22.

Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183054
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.11.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354556PMC
January 2019

ARID1A Gene Driver Mutations in Lung Adenocarcinomas.

J Thorac Oncol 2018 12;13(12):e255-e257

Catalan Institute of Oncolgy, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol, Badalona, Spain; Institute of Oncology Rosell, Quiron-Dexeus University Institute; and Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.07.099DOI Listing
December 2018

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Transl Lung Cancer Res 2018 Dec;7(6):691-702

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.06.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249614PMC
December 2018

Tumor mutational burden as predictive factor of response to immunotherapy.

Transl Lung Cancer Res 2018 Dec;7(Suppl 4):S358-S361

Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Quironsalud Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.10.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328696PMC
December 2018

Avelumab in non-small-cell lung cancer.

Lancet Oncol 2018 11 24;19(11):1423-1424. Epub 2018 Sep 24.

Dr Rosell Oncology Institute, University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30683-1DOI Listing
November 2018

Rhomboids and regulation of receptor tyrosine kinase ligands shedding.

EBioMedicine 2018 Nov 6;37:19-20. Epub 2018 Oct 6.

Catalan Institute of Oncology, Germans Trias i Pujol Research Institute and Hospital, Badalona, Barcelona 08028, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183041
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.09.053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284349PMC
November 2018

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.

Expert Rev Anticancer Ther 2018 10 14;18(10):1021-1030. Epub 2018 Aug 14.

c Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology , Quirón-Dexeus University Institute , Barcelona , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2018.1508347DOI Listing
October 2018

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

J Thorac Oncol 2018 09 8;13(9):1324-1337. Epub 2018 May 8.

Instituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Catalan Institute of Oncology and Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.030DOI Listing
September 2018

Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma.

Lancet Respir Med 2018 09 17;6(9):649-651. Epub 2018 Jul 17.

Germans Trias i Pujol Research Institute, Barcelona, Spain; Institute of Oncology, University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30292-3DOI Listing
September 2018

Inhibition of MEK, a canonical KRAS pathway effector in mutant NSCLC.

Transl Lung Cancer Res 2018 Sep;7(Suppl 3):S183-S186

Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.03.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193900PMC
September 2018

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Transl Lung Cancer Res 2018 Sep;7(Suppl 3):S198-S201

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/22760/18264
Publisher Site
http://dx.doi.org/10.21037/tlcr.2018.07.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193917PMC
September 2018

Activation of viral defense signaling in cancer.

Ther Adv Med Oncol 2018 29;10:1758835918793105. Epub 2018 Aug 29.

Rosell Oncology Institute (IOR), Dexeus University Hospital, Quironsalud Group, Barcelona, Spain Rosell Oncology Institute (IOR), Sagrat Cor University Hospital, Quironsalud Group, Barcelona, Spain Catalan Institute of Oncology, Germans Trias I Pujol University Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918793105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116077PMC
August 2018

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer.

EBioMedicine 2018 07;33:16-17

Medical Oncology Department, University Hospital Sagrat Cor, QuironSalud Group, Institute of Oncology Rosell, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085495PMC
July 2018

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.

Curr Oncol Rep 2018 07 20;20(9):70. Epub 2018 Jul 20.

Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0720-zDOI Listing
July 2018

RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants.

Arch Pathol Lab Med 2018 Apr;142(4):474-479

From the Department of Pathology, Hospital Clínic, Barcelona, Spain (Dr Teixidó); Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Dr Teixidó); Pangaea Oncology, Oncology Laboratory, Dexeus University Hospital - Quirónsalud Group, Barcelona, Spain (Ms Giménez-Capitán and Drs Molina-Vila, Peg, Karachaliou, Castellví, and Rosell); the Department of Pathology, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Peg and Castellví); Morphological Sciences Department, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Peg and Castellví); Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor and Quirónsalud Group, Barcelona, Spain (Drs Karachaliou and Rosell); the Department of Medical Oncology, Canarias University Hospital, San Cristóbal de La Laguna, Tenerife, Spain (Dr Rodríguez-Capote); and Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain (Dr Rosell).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0134-RADOI Listing
April 2018

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.

Ther Adv Med Oncol 2018 2;10:1758835918763744. Epub 2018 Apr 2.

Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918763744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888808PMC
April 2018

Liquid biopsy for lung cancer early detection.

J Thorac Dis 2018 Apr;10(Suppl 7):S882-S897

Cancer Biology and Precision Medicine Program, Germans Trias i Pujol University Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/20370/15798
Publisher Site
http://dx.doi.org/10.21037/jtd.2018.03.81DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945693PMC
April 2018

Osimertinib in untreated epidermal growth factor receptor ()-mutated advanced non-small cell lung cancer.

Transl Lung Cancer Res 2018 Apr;7(Suppl 2):S165-S170

Medical Oncology Unit, Department of Human Pathology of Adult and Evolutive Age "G. Barresi", University of Messina, Messina, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2018.03.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943214PMC
April 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.

Lancet Oncol 2018 03;19(3):e126

University Hospital Sagrat Cor, Quirónsalud Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30071-8DOI Listing
March 2018

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.

Ther Adv Med Oncol 2018 22;10:1758835918763723. Epub 2018 Mar 22.

Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918763723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871042PMC
March 2018

Clinical assessment of immune-related adverse events.

Ther Adv Med Oncol 2018 30;10:1758835918764628. Epub 2018 Mar 30.

Department of Medical Oncology, Dr Rosell Oncology Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918764628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882039PMC
March 2018

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Ther Adv Med Oncol 2018 9;10:1758834017745012. Epub 2018 Jan 9.

Instituto Oncológico Dr Rosell (IOR), University Hospital General de Catalunya, Sant Cugat del Vallès, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017745012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784559PMC
January 2018

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Ther Adv Med Oncol 2018 18;10:1758834017749748. Epub 2018 Jan 18.

Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017749748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784541PMC
January 2018

BRAF and BRAF-inactivating mutations in NSCLC.

Lancet Oncol 2017 10 11;18(10):1286-1287. Epub 2017 Sep 11.

Dr Rosell Oncology Institute, University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30678-2DOI Listing
October 2017

Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

J Thorac Dis 2017 Oct;9(Suppl 13):S1364-S1372

Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.09.59DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676104PMC
October 2017

Brain metastases in patients with EGFR-mutant non-small-cell lung cancer.

Lancet Respir Med 2017 09 19;5(9):669-671. Epub 2017 Jul 19.

Instituto Oncológico Dr Rosell, University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(17)30265-5DOI Listing
September 2017

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Cancer Cell 2017 08;32(2):238-252.e9

Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 149 13(th) Street, Charlestown, MA 02129, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.07.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381325PMC
August 2017

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Lung Cancer (Auckl) 2017 18;8:109-125. Epub 2017 Aug 18.

Department of Oncology, Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S119644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571822PMC
August 2017

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Expert Rev Respir Med 2017 06 15;11(6):469-479. Epub 2017 May 15.

e Medical Oncology Unit, Department of Human Pathology "G. Barresi" , University of Messina , Messina , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2017.1326822DOI Listing
June 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Beyond platinum treatment for NSCLC: what does the future hold?

Expert Rev Anticancer Ther 2017 04 8;17(4):293-295. Epub 2017 Feb 8.

c Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1288103DOI Listing
April 2017

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.

Int J Biol Markers 2017 Mar 2;32(1):e90-e95. Epub 2017 Mar 2.

 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona - Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/jbm.5000223DOI Listing
March 2017

HER3 as a Therapeutic Target in Cancer.

BioDrugs 2017 Feb;31(1):63-73

Germans Trias i Pujol Research Institute, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-016-0205-2DOI Listing
February 2017

Pharmacological management of relapsed/refractory NSCLC with chemical drugs.

Expert Opin Pharmacother 2017 Feb 29;18(3):295-304. Epub 2017 Jan 29.

e Cancer Biology & Precision Medicine Program , Institut d'Investigació en Ciències Germans Trias i Pujol , Badalona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1285284DOI Listing
February 2017

Feasibility of cell-free circulating tumor DNA testing for lung cancer.

Biomark Med 2016 14;10(4):417-30. Epub 2016 Mar 14.

Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm.16.6DOI Listing
December 2016

RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.

Lancet Oncol 2016 12 4;17(12):1623-1625. Epub 2016 Nov 4.

Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain; University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30557-5DOI Listing
December 2016

Liquid Biopsy in Non-Small Cell Lung Cancer.

Front Med (Lausanne) 2016 23;3:69. Epub 2016 Dec 23.

Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2016.00069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179978PMC
December 2016

Human endogenous retroviruses and cancer.

Cancer Biol Med 2016 Dec;13(4):483-488

Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona 08028, Spain; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias I Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, 08916, Spain; Fundación Molecular Oncology Research, Barcelona 08028, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250606PMC
December 2016

Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 10 18;34(28):3361-2. Epub 2016 Jul 18.

Germans Trias i Pujol Health Sciences Research Institute, Badalona; and University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.3458DOI Listing
October 2016

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients.

Transl Lung Cancer Res 2016 Oct;5(5):525-531

Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain;; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain;; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain;; Autonomous University of Barcelona (UAB), Campus Can Ruti, Badalona, Spain;; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.09.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099519PMC
October 2016

Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report.

Transl Lung Cancer Res 2016 Oct;5(5):532-537

Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain;; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain;; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Triasi Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.10.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099508PMC
October 2016

Annual or biennial lung cancer CT screening?

J Thorac Dis 2016 Sep;8(9):2424-2426

Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain;; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.09.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059240PMC
September 2016

Unraveling the genomic complexity of small cell lung cancer.

Transl Lung Cancer Res 2016 Aug;5(4):363-6

Autonomous University of Barcelona, Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain;; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2016.07.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009089PMC
August 2016

Recent developments in the use of immunotherapy in non-small cell lung cancer.

Expert Rev Respir Med 2016 07 13;10(7):781-98. Epub 2016 May 13.

e Dr Rosell Oncology Institute , Quirón Dexeus University Hospital , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2016.1182866DOI Listing
July 2016

Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease.

Nat Rev Clin Oncol 2016 07 1;13(7):401-2. Epub 2016 Jun 1.

Germans Trias i Pujol Health Sciences Institute, Campus Can Ruti, Carretera de Can Ruti, Cami de les Escoles S/N, Badalona, Barcelona 08916, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.83DOI Listing
July 2016

Trends in immunotherapy for brain metastases.

Lancet Oncol 2016 07 3;17(7):859-860. Epub 2016 Jun 3.

Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain; University Hospital Sagrat Cor, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30091-2DOI Listing
July 2016

Large-scale screening for somatic mutations in lung cancer.

Lancet 2016 Apr 15;387(10026):1354-1356. Epub 2016 Jan 15.

Autonomous University of Barcelona, Germans Trias i Pujol Health Sciences Research Institute and Hospital, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)01125-3DOI Listing
April 2016

Cellular and molecular biology of small cell lung cancer: an overview.

Transl Lung Cancer Res 2016 Feb;5(1):2-15

1 Instituto Oncolόgico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 7 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2016.01.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758976PMC
February 2016

Targeted drugs in small-cell lung cancer.

Transl Lung Cancer Res 2016 Feb;5(1):51-70

1 Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy ; 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2016.01.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758978PMC
February 2016

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.

Transl Lung Cancer Res 2015 Dec;4(6):704-12

1 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 2 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 3 Istituto Nazionale Tumori, Milano, Italy ; 4 Italian Medicines Agency, Roma, Italy ; 5 Pangaea Biotech, Barcelona, Spain ; 6 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700216PMC
December 2015

Platelets and their role in cancer evolution and immune system.

Transl Lung Cancer Res 2015 Dec;4(6):713-20

1 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700232PMC
December 2015

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.

Transl Lung Cancer Res 2015 Dec;4(6):721-7

1 Medical Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700230PMC
December 2015

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Transl Lung Cancer Res 2015 Dec;4(6):728-42

1 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Pangaea Biotech, Barcelona, Spain ; 4 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain ; 5 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700220PMC
December 2015

Immunotherapy meets targeted therapy: will this team end the war against cancer?

Transl Lung Cancer Res 2015 Dec;4(6):752-5

1 Rosell Oncology Institute, Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Institut Quimic de Sarriá, Barcelona, Spain ; 4 Institut Catalá d'Oncologia, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700229PMC
December 2015

Melanoma: oncogenic drivers and the immune system.

Ann Transl Med 2015 Oct;3(18):265

1 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Quirón Dexeus University Institute, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy ; 6 Instituto Oncológico de Córdoba, Córdoba, Argentina ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.08.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630557PMC
October 2015

Other targeted drugs in melanoma.

Ann Transl Med 2015 Oct;3(18):266

1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.08.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630555PMC
October 2015